JULUCA 50 mg/25 mg, comprimé pelliculé

( ARTG ) JULUCA (dolutegravir/rilpivirine) is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults who are virologically-su‍‍‍‍‍‍​​​‍​​​​​​ppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor (see section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials).